Assocaiton Between Uric Acid Trajecteries and Remission of NAFLD in NAFLD Individuals

Sponsor

Ningbo No. 1 Hospital (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05245890

Collaborator

The First Afliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China (Other)

2,000

Enrollment

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

Uric acid is the end product of dietary or endogenous purines degradation, and hyperuricemia is one of the most common metabolic disorders. A growing body of evidence, comprising a great deal of cross-sectional studies and several prospective ones, also indicates that hyperuricemia is associated with increased prevalence, incidence, and disease severity of non-alcoholic fatty liver disease (NAFLD).

Capitalizing on a cohort study in China, the investigators are aimed to assess the associations of SUA trajecteries with remission of NAFLD in NAFLD individuals and examined whether the association differs across subpopulations.

Condition or Disease	Intervention/Treatment	Phase
Non-Alcoholic Fatty Liver Disease Hyperuricemia

Detailed Description

A cohort study was conducted to evaluate the relationship between the SUA trajecteries and remission of NAFLD. The study enrolled employees who were attending their annual health examination. Furrhermore, the investigators are aimed to explore whether the association differs across subpopulations.

Study Design

Study Type:

Observational [Patient Registry]

Anticipated Enrollment :

2000 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

Assocaiton Between Uric Acid Trajecteries and Remission of Non-alcoholic Fatty Liver Disease (NAFLD) in NAFLD Individuals

Anticipated Study Start Date :

Mar 1, 2022

Anticipated Primary Completion Date :

Mar 1, 2023

Anticipated Study Completion Date :

Mar 1, 2024

Outcome Measures

Primary Outcome Measures

the severity fatty liver evaluated by hepatic ultrasonic examination [2 years]
Hepatic ultrasonic examination was performed in all subjects by a trained ultrasonographist who was unaware of the clinical and laboratory data. Hepatic steatosis was diagnosed by characteristic echo patterns according to conventional criteria, such as the evidence of diffuse hyperechogenicity of the liver relative to the kidneys, ultrasound beam attenuation, and poor visualization of intrahepatic structures.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 80 Years

Sexes Eligible for Study:

All

Inclusion Criteria:

age >=18 years;
agree to be enrolled in this study.

Exclusion Criteria:

those taking antihypertensive or antidiabetic agents, lipid-lowing agents, or hypouricemic agents;
those with alcohol consumption greater than 140 g/week for men and 70 g/week for women;
those with a history of other known causes of chronic liver disease such as viral hepatitis or autoimmune hepatitis, and those using hepatotoxic medications.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

Ningbo No. 1 Hospital
The First Afliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Ningbo No. 1 Hospital

ClinicalTrials.gov Identifier:

NCT05245890

Other Study ID Numbers:

uric acid trajecteries2022

First Posted:

Feb 18, 2022

Last Update Posted:

Feb 18, 2022

Last Verified:

Feb 1, 2022

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Additional relevant MeSH terms:

Liver Diseases

Fatty Liver

Non-alcoholic Fatty Liver Disease

Hyperuricemia

Study Results

No Results Posted as of Feb 18, 2022